Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC

Phase 2 Unknown 35 enrolled Nanfang Hospital, Southern Medical University

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Camrelizumab in combination with apatinib plus NK cell in patients with advanced hepatocellular carcinoma.

Timeline

Start: 2021-01-01
Primary completion: 2022-12-31
Completion: 2023-12-31

Publications

Uong TNT, Yoon M, Chung IJ, Nam TK, Ahn SJ, Jeong JU, Song JY, Kim YH, Nguyen HPQ, Cho D, Chu TH, Dang GC, Nguyen NPNM. Direct Tumor Irradiation Potentiates Adoptive NK Cell Targeting Against Parental and Stemlike Cancer in Human Liver Cancer Models. Int J Radiat Oncol Biol Phys. 2024 May 1;119(1):234-250. doi: 10.1016/j.ijrobp.2023.11.023. Epub 2023 Nov 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Camrelizumab	Monoclonal antibody	200 mg	Intravenous
Subject	NK cell	Cell therapy	1e+09 cells	Intravenous
Subject	Rivoceranib	Small molecule	250 mg	Oral

Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC

Summary

Timeline

Publications

Drugs

Indications